|801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.Chinafirstname.lastname@example.org|
|Place of Origin:||China|
|Minimum Order Quantity:||one million tablets|
|Payment Terms:||L/C, T/T|
|Supply Ability:||One million pills per day|
|Product:||Pentoxifylline Tablets 400mg Modified-release||Specification:||400mg|
Pentoxifylline tablets 400mg Modified-release 400mg Oral Medications
Product : Pentoxifylline tablets 400mg Modified-release
Specification : 400mg
Standard : BP, USP
Packing : 10’s/box
A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.
For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
Mechanism of action
Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
Contact Person: Luke Liu